A. Schanne
University of Pennsylvania
5 Papers
35 Citations
A. Schanne is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Population & Intrauterine device. The author has an hindex of 4, co-authored 5 publications. Previous affiliations of A. Schanne include Hospital of the University of Pennsylvania.
Chat about Author
Papers
Contraceptive use and the role of contraceptive counseling in reproductive-aged women with cancer☆☆☆
Bat-Sheva L. Maslow,Christopher B. Morse,A. Schanne,Alison W. Loren,Susan M. Domchek,Clarisa R. Gracia +5 more
TL;DR: In this article, the authors characterized contraceptive use during cancer treatment in a group of reproductive-aged women with a recent cancer diagnosis and assessed the impact of contraceptive counseling on the methods they selected.
46
Original research article Contraceptive use and the role of contraceptive counseling in reproductive-aged women with cancer ☆,☆☆
Bat-Sheva L. Maslow,Christopher B. Morse,A. Schanne,Alison W. Loren,Susan M. Domchek,Clarisa R. Gracia +5 more
- 01 Jan 2014
TL;DR: In this paper, the authors characterized contraceptive use during cancer treatment in a group of reproductive-aged women with a recent cancer diagnosis and assessed the impact of contraceptive counseling on the methods they selected.
32
Female cancer survivors exposed to alkylating-agent chemotherapy have unique reproductive hormone profiles
Lauren N.C. Johnson,Mary D. Sammel,A. Schanne,L. Lechtenberg,Maureen Prewitt,Clarisa R. Gracia +5 more
TL;DR: Women exposed to alkylating agents have a unique reproductive hormone milieu that is not solely explained by age or ovarian reserve, and the urinary hormone profile observed in survivors appears more similar to same-age control subjects than to late-reproductive-age women with similar ovarian reserve.
5
Antimüllerian hormone levels are lower in BRCA2 mutation carriers.
Lauren N.C. Johnson,Mary D. Sammel,Susan M. Domchek,A. Schanne,Maureen Prewitt,Clarisa R. Gracia +5 more
TL;DR: Comparison of antimüllerian hormone levels in women at high risk for hereditary breast and ovarian cancer compared with healthy low-risk control women observed significantly lower AMH levels among BRCA2 carriers compared with low- risk control women.
Antimüllerian hormone and antral follicle count are lower in female cancer survivors and healthy women taking hormonal contraception
Lauren N.C. Johnson,Mary D. Sammel,Katherine E. Dillon,L. Lechtenberg,A. Schanne,Clarisa R. Gracia +5 more
TL;DR: AMH and AFC are significantly lower among women with recent exposure to HC, and should be interpreted with caution when measured in the setting of recent hormone use.